Candriam Luxembourg S.C.A. Sells 1,003 Shares of Edwards Lifesciences Corp (EW)

Candriam Luxembourg S.C.A. reduced its position in shares of Edwards Lifesciences Corp (NYSE:EW) by 4.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 23,603 shares of the medical research company’s stock after selling 1,003 shares during the period. Candriam Luxembourg S.C.A.’s holdings in Edwards Lifesciences were worth $3,615,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Parallel Advisors LLC increased its stake in shares of Edwards Lifesciences by 11.2% in the fourth quarter. Parallel Advisors LLC now owns 684 shares of the medical research company’s stock worth $101,000 after buying an additional 69 shares during the last quarter. BB&T Securities LLC increased its stake in shares of Edwards Lifesciences by 0.9% in the fourth quarter. BB&T Securities LLC now owns 8,179 shares of the medical research company’s stock worth $1,252,000 after buying an additional 70 shares during the last quarter. First Personal Financial Services increased its stake in shares of Edwards Lifesciences by 42.7% in the fourth quarter. First Personal Financial Services now owns 244 shares of the medical research company’s stock worth $37,000 after buying an additional 73 shares during the last quarter. Biondo Investment Advisors LLC increased its stake in shares of Edwards Lifesciences by 4.3% in the fourth quarter. Biondo Investment Advisors LLC now owns 1,800 shares of the medical research company’s stock worth $276,000 after buying an additional 75 shares during the last quarter. Finally, Whittier Trust Co. of Nevada Inc. increased its stake in shares of Edwards Lifesciences by 48.7% in the fourth quarter. Whittier Trust Co. of Nevada Inc. now owns 235 shares of the medical research company’s stock worth $36,000 after buying an additional 77 shares during the last quarter. 83.09% of the stock is currently owned by institutional investors and hedge funds.

EW has been the subject of several recent research reports. Raymond James boosted their target price on shares of Edwards Lifesciences from $160.00 to $175.00 and gave the company an “outperform” rating in a research note on Thursday, December 6th. Citigroup boosted their target price on shares of Edwards Lifesciences from $118.00 to $119.00 and gave the company a “sell” rating in a research note on Wednesday, January 2nd. Morgan Stanley boosted their target price on shares of Edwards Lifesciences from $157.00 to $180.00 and gave the company an “overweight” rating in a research note on Friday, December 7th. BMO Capital Markets boosted their target price on shares of Edwards Lifesciences to $204.00 and gave the company an “outperform” rating in a research note on Friday. Finally, Canaccord Genuity boosted their target price on shares of Edwards Lifesciences from $177.00 to $186.00 and gave the company a “positive” rating in a research note on Wednesday, January 16th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and thirteen have issued a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $178.00.



In other news, VP Catherine M. Szyman sold 1,146 shares of the company’s stock in a transaction dated Friday, March 15th. The shares were sold at an average price of $179.10, for a total transaction of $205,248.60. Following the completion of the transaction, the vice president now owns 22,229 shares in the company, valued at $3,981,213.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Michael A. Mussallem sold 32,800 shares of the company’s stock in a transaction dated Thursday, January 3rd. The stock was sold at an average price of $143.90, for a total transaction of $4,719,920.00. Following the transaction, the chief executive officer now owns 75,926 shares of the company’s stock, valued at approximately $10,925,751.40. The disclosure for this sale can be found here. Insiders have sold 136,868 shares of company stock valued at $22,406,044 in the last 90 days. Insiders own 1.84% of the company’s stock.

Edwards Lifesciences stock opened at $188.99 on Friday. The stock has a market cap of $39.27 billion, a PE ratio of 40.21, a PEG ratio of 2.44 and a beta of 0.90. The company has a debt-to-equity ratio of 0.19, a current ratio of 2.61 and a quick ratio of 1.92. Edwards Lifesciences Corp has a one year low of $123.00 and a one year high of $197.86.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, January 31st. The medical research company reported $1.17 EPS for the quarter, hitting the consensus estimate of $1.17. The business had revenue of $977.70 million during the quarter, compared to analyst estimates of $973.72 million. Edwards Lifesciences had a net margin of 19.40% and a return on equity of 31.09%. During the same quarter in the prior year, the firm earned $0.94 earnings per share. Equities research analysts predict that Edwards Lifesciences Corp will post 5.21 EPS for the current year.

TRADEMARK VIOLATION WARNING: This report was first published by Dakota Financial News and is owned by of Dakota Financial News. If you are accessing this report on another site, it was illegally stolen and republished in violation of international copyright laws. The original version of this report can be read at https://dakotafinancialnews.com/2019/03/24/candriam-luxembourg-s-c-a-sells-1003-shares-of-edwards-lifesciences-corp-ew.html.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.

Recommended Story: Dow Jones Industrial Average (DJIA)

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.